Collectively, our in vivo data demonstrated that shikonin treatment results in a durable therapeutic response and can be an effective treatment in preselected SDHA- and LRPPRC-overexpressing ovarian tumors, which introduces hope for improving current therapies for ovarian cancer patients. This evidence concerns the gene LRPPRC and ovarian cancer.